Содержание фибронектина в сыворотке крови больных сахарным диабетом 1-го типа с микроангиопатиями, болеющих с детства, и у лиц с ожирением

Микро- и макроангиопатии - основная причина инвалидности и смертности при сахарном диабете. Эндотелиальная дисфункция - ранний и важный этап развития диабетических ангиопатий. Содержание циркулирующего фибронектина может быть одним из маркеров эндотелиальной дисфункции. Нами обнаружено повышение содержания фибронектина в сыворотке больных сахарным диабетом 1-го типа c микроангиопатиями и у лиц с ожирением, которое коррелировало с индексом массы тела, показателями углеводного и липидного обмена. Выявленные сдвиги могут служить маркером эндотелиальной дисфункции при указанных патологических состояниях.

фибронектин, эндотелиальная дисфункция, сахарный диабет 1-го типа, микроангиопатии, ожирение

1. Larsen J, Brekke M, Sandvik L, et al. Silent Coronary Atheromatosis in Type 1 Diabetic Patients and Its Relation to Long-Term Glycemic Control. Diabetes. 2002;51(8):2637-2641. doi: 10.2337/diabetes.51.8.2637.

2. Jarvisalo MJ. Endothelial Dysfunction and Increased Arterial Intima-Media Thickness in Children With Type 1 Diabetes. Circulation. 2004;109(14):1750-1755. doi: 10.1161/01.cir.0000124725.46165.2c

3. Schoenhagen P, Nissen S. Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound. Current Drug Target -Cardiovascular & Hematological Disorders. 2003;3(3):218-226. doi: 10.2174/1568006033481401

4. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48(9):1856-1862. doi: 10.2337/diabetes.48.9.1856

5. Williams SB, Cusco JA, Roddy M-A, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1996;27(3):567-574. doi: 10.1016/0735-1097(95)00522-6.

6. Hynes RO. Fibronectins. Sci. Am. 1986;254(6):42-51. doi: 10.1038/scientificamerican0686-42

7. Tomasini-Johansson BR, Annis DS, Mosher DF. The N-terminal 70-kDa fragment of fibronectin binds to cell surface fibronectin assembly sites in the absence of intact fibronectin. Matrix Biol. 2006;25(5):282-293. doi: 10.1016/j.matbio.2006.02.002.

8. Singh P, Carraher C, Schwarzbauer JE. Assembly of Fibronectin Extracellular Matrix. Annu. Rev. Cell Dev. Biol. 2010;26(1):397-419. doi: 10.1146/annurev-cellbio-100109-104020

9. Kanters SDJM, Banga JD, Algra A, et al. Plasma Levels of Cellular Fibronectin in Diabetes. Diabetes Care. 2001;24(2):323-327. doi: 10.2337/diacare.24.2.323

10. Olsen AL, Sackey BK, Marcinkiewicz C, et al. Fibronectin Extra Domain-A Promotes Hepatic Stellate Cell Motility but Not Differentiation Into Myofibroblasts. Gastroenterology. 2012;142(4):928-937.e923. doi: 10.1053/j.gastro.2011.12.038

11. Bauters C, Marotte F, Hamon M, et al. Accumulation of Fetal Fibronectin mRNAs After Balloon Denudation of Rabbit Arteries. Circulation. 1995;92(4):904-911. doi: 10.1161/01.cir.92.4.904

12. Habib SL, Yadav M, Tizani S, et al. Tuberin Inhibits Production of the Matrix Protein Fibronectin in Diabetes. J. Am. Soc. Nephrol. 2012;23(10):1652-1662. doi: 10.1681/asn.2012030285

13. Trudeau K, Roy S, Guo W, et al. Fenofibric Acid Reduces Fibronectin and Collagen Type IV Overexpression in Human Retinal Pigment Epithelial Cells Grown in Conditions Mimicking the Diabetic Milieu: Functional Implications in Retinal Permeability. Invest. Ophthalmol. Vis. Sci. 2011;52(9):6348-6354. doi: 10.1167/iovs.11-7282

14. Lim Y, Jo DH, Kim JH, et al. Human Apolipoprotein(a) Kringle V Inhibits Ischemia-Induced Retinal Neovascularization via Suppression of Fibronectin-Mediated Angiogenesis. Diabetes. 2012;61(6):1599-1608. doi: 10.2337/db11-1541

15. Rohwedder I, Montanez E, Beckmann K, et al. Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Mol. Med. 2012;4(7):564-576. doi: 10.1002/emmm.201200237

16. Chiang HY, Korshunov VA, Serour A, et al. Fibronectin Is an Important Regulator of Flow-Induced Vascular Remodeling. Arterioscler. Thromb. Vasc. Biol. 2009;29(7):1074-1079. doi: 10.1161/atvbaha.108.181081

17. Aziz-Seible RS. Fibronectin: Functional character and role in alcoholic liver disease. World J. Gastroenterol. 2011;17(20):2482. doi: 10.3748/wjg.v17.i20.2482

18. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93(11):3798-3802.

19. van Beers JJBC, Willemze A, Stammen-Vogelzangs J, et al. Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles. Arthritis Res. Ther. 2012;14(1):R35. doi: 10.1186/ar3744

20. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The Association Between a Family History of Type 2 Diabetes and Coronary Artery Disease in a Type 1 Diabetes Population. Diabetes Care. 1998;21(4):610-614. doi: 10.2337/diacare.21.4.610

21. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J. Diabetes Complications. 2000;14(4):197-200. doi: 10.1016/s1056-8727(00)00083-0

22. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor Glycemic Control Predicts Coronary Heart Disease Events in Patients With Type 1 Diabetes Without Nephropathy. Arterioscler. Thromb. Vasc. Biol. 1999;19(4):1014-1019. doi: 10.1161/01.atv.19.4.1014

23. Adameova A, Dhalla NS. Role of microangiopathy in diabetic cardiomyopathy. Heart Fail. Rev. 2013;19(1):25-33. doi: 10.1007/s10741-013-9378-7

24. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181-187. doi: 10.1016/j.metabol.2013.10.002